Aclaris Therapeutics (ACRS) Financials

$4.53 +0.08 (+1.80%)

Closing price 05/20/2026 04:00 PM Eastern

Extended Trading

$4.37 -0.16 (-3.53%)

As of 07:31 AM Eastern

Annual Income Statements for Aclaris Therapeutics

This table shows Aclaris Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-23	-48	-69	-293	-161	-51	-91	-87	-88	-132	-65
Consolidated Net Income / (Loss)	-21	-48	-69	-133	-161	-51	-91	-87	-88	-132	-65
Net Income / (Loss) Continuing Operations	-21	-48	-52	-161	-114	-51	-91	-87	-88	-132	-65
Total Pre-Tax Income	-21	-48	-70	-82	-114	-51	-91	-87	-89	-142	-76
Total Operating Income	-21	-49	-54	-79	-111	-51	-90	-90	-97	-142	-76
Total Gross Profit	0.00	0.00	0.48	7.97	0.17	1.35	2.05	26	28	16	5.74
Total Revenue	0.00	0.00	1.68	12	4.23	6.48	6.76	30	31	19	7.83
Operating Revenue	0.00	0.00	1.68	12	4.23	6.48	6.76	30	31	19	7.83
Total Cost of Revenue	0.00	0.00	1.21	4.33	4.06	5.13	4.71	4.02	3.42	2.79	2.09
Operating Cost of Revenue	0.00	0.00	1.21	4.33	4.06	5.13	4.71	4.02	3.42	2.79	2.09
Total Operating Expenses	21	49	55	87	111	52	92	116	125	158	82
Selling, General & Admin Expense	5.33	12	19	26	28	21	24	25	32	22	22
Research & Development Expense	15	33	36	61	64	29	44	78	105	120	53
Other Operating Expenses / (Income)	-	0.00	-	-	-	0.00	0.00	7.94	15	13	5.19
Other Special Charges / (Income)	-	-	-	-	0.73	2.39	24	4.70	-27	2.50	2.30
Total Other Income / (Expense), net	0.10	0.49	0.00	0.00	-2.48	-0.42	-1.14	2.95	8.51	0.00	0.00
Other Gains / (Losses), net	-	-	2.07	-82	-	-	-	-	-	9.87	11
Basic Earnings per Share	($3.79)	($2.25)	($2.44)	($4.03)	($3.90)	($1.20)	($1.60)	($1.33)	($1.27)	($1.71)	($0.53)
Weighted Average Basic Shares Outstanding	6.11M	21.42M	28.10M	32.91M	41.32M	42.54M	56.73M	65.21M	69.81M	77.30M	122.56M
Diluted Earnings per Share	($3.79)	($2.25)	($2.44)	($4.03)	($3.90)	($1.20)	($1.60)	($1.33)	($1.27)	($1.71)	($0.53)
Weighted Average Diluted Shares Outstanding	6.11M	21.42M	28.10M	32.91M	41.32M	42.54M	56.73M	65.21M	69.81M	77.30M	122.56M
Weighted Average Basic & Diluted Shares Outstanding	6.11M	21.42M	28.10M	32.91M	41.32M	42.54M	61.28M	66.69M	70.93M	107.92M	120.60M

This table shows Aclaris Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-29	-1.49	-17	-11	-7.59	-97	-15	-15	-15	-20	-20
Consolidated Net Income / (Loss)	-29	-1.49	-17	-11	-7.59	-97	-15	-15	-15	-20	-20
Net Income / (Loss) Continuing Operations	-29	-1.49	-17	-11	-7.59	-97	-15	-15	-15	-20	-20
Total Pre-Tax Income	-32	2.70	-19	-13	-10	-92	-18	-18	-17	-23	-22
Total Operating Income	-32	-4.05	-19	-13	-10	-100	-18	-18	-17	-23	-22
Total Gross Profit	8.43	17	1.59	2.14	3.69	8.51	0.95	1.26	2.76	0.76	1.60
Total Revenue	9.28	18	2.40	2.77	4.35	9.21	1.46	1.78	3.30	1.30	2.00
Operating Revenue	9.28	18	2.40	2.77	4.35	9.21	1.46	1.78	3.30	1.30	2.00
Total Cost of Revenue	0.85	0.73	0.81	0.62	0.65	0.71	0.51	0.52	0.54	0.53	0.40
Operating Cost of Revenue	0.85	0.73	0.81	0.62	0.65	0.71	0.51	0.52	0.54	0.53	0.40
Total Operating Expenses	40	21	21	15	14	108	19	20	20	23	24
Selling, General & Admin Expense	7.09	8.21	6.84	4.75	5.65	4.95	6.14	5.39	4.87	5.58	6.74
Research & Development Expense	24	33	9.85	8.76	5.96	96	12	11	13	17	16
Other Operating Expenses / (Income)	7.34	5.70	1.03	1.29	1.75	8.60	1.01	1.34	1.91	0.94	1.39
Other Special Charges / (Income)	1.70	-26	2.80	0.20	0.80	-1.30	0.30	1.50	0.10	0.40	0.00
Total Other Income / (Expense), net	0.00	6.75	0.00	0.00	0.00	8.00	0.00	0.00	0.00	-	0.00
Other Gains / (Losses), net	2.32	-	1.99	1.87	2.89	-	3.00	2.98	2.54	2.94	2.37
Basic Earnings per Share	($0.41)	($0.02)	($0.24)	($0.15)	($0.11)	($1.21)	($0.12)	($0.13)	($0.12)	($0.16)	($0.15)
Weighted Average Basic Shares Outstanding	70.81M	69.81M	71.07M	71.29M	71.38M	77.30M	122.39M	122.58M	122.62M	122.56M	128.81M
Diluted Earnings per Share	($0.41)	($0.02)	($0.24)	($0.15)	($0.11)	($1.21)	($0.12)	($0.13)	($0.12)	($0.16)	($0.15)
Weighted Average Diluted Shares Outstanding	70.81M	69.81M	71.07M	71.29M	71.38M	77.30M	122.39M	122.58M	122.62M	122.56M	128.81M
Weighted Average Basic & Diluted Shares Outstanding	70.84M	70.93M	71.26M	71.34M	71.43M	107.92M	108.28M	108.33M	108.35M	120.60M	139.66M

This table details how cash moves in and out of Aclaris Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-0.91	20	-9.97	37	-21	-14	5.29	18	-5.40	-15	-4.61
Net Cash From Operating Activities	-20	-35	-55	-101	-96	-39	-52	-68	-78	-20	-47
Net Cash From Continuing Operating Activities	-20	-35	-55	-101	-96	-39	-52	-68	-78	-20	-47
Net Income / (Loss) Continuing Operations	-21	-48	-69	-133	-161	-51	-91	-87	-88	-132	-65
Consolidated Net Income / (Loss)	-21	-48	-69	-133	-161	-51	-91	-87	-88	-132	-65
Depreciation Expense	0.09	0.12	0.40	1.88	6.41	1.32	0.92	0.80	0.86	0.81	0.45
Non-Cash Adjustments To Reconcile Net Income	1.18	9.10	14	19	60	11	15	15	27	93	19
Changes in Operating Assets and Liabilities, net	-1.08	4.27	-0.97	11	-1.97	-0.15	23	3.51	-18	18	-1.17
Net Cash From Investing Activities	-77	-62	-56	9.37	106	6.39	-168	13	46	-70	48
Net Cash From Continuing Investing Activities	-77	-62	-56	9.37	106	6.39	-168	13	46	-70	48
Purchase of Property, Plant & Equipment	-0.51	-0.23	-1.24	-1.36	-1.61	-0.45	-0.31	-0.61	-1.31	-0.12	-0.11
Acquisitions	0.00	0.00	-9.65	-67	-	-	-	-	0.00	-36	0.00
Purchase of Investments	-83	-149	-197	-162	-137	-48	-235	-165	-136	-120	-40
Sale and/or Maturity of Investments	6.07	87	153	239	210	55	68	178	183	86	89
Other Investing Activities, net	-	-	-	0.00	34	-	-	-	-	0.00	-0.83
Net Cash From Financing Activities	96	117	100	128	-30	18	225	73	27	75	-5.86
Net Cash From Continuing Financing Activities	96	117	100	128	-30	18	225	73	27	75	-5.86
Other Financing Activities, net	0.00	0.12	20	-1.85	-0.32	7.67	-1.67	73	27	75	-5.86

This table details how cash moves in and out of Aclaris Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	7.89	0.84	-4.04	-13	25	-23	5.79	-4.96	-0.15	-5.30	8.70
Net Cash From Operating Activities	-25	-6.76	-21	-12	22	-8.94	-13	-9.99	-11	-13	-18
Net Cash From Continuing Operating Activities	-25	-6.76	-21	-12	22	-8.94	-13	-9.99	-11	-13	-18
Net Income / (Loss) Continuing Operations	-29	-1.49	-17	-11	-7.59	-97	-15	-15	-15	-20	-20
Consolidated Net Income / (Loss)	-29	-1.49	-17	-11	-7.59	-97	-15	-15	-15	-20	-20
Depreciation Expense	0.22	0.23	0.24	0.24	0.18	0.14	0.13	0.11	0.11	0.10	0.10
Non-Cash Adjustments To Reconcile Net Income	5.95	7.90	2.09	2.90	6.70	90	12	3.06	9.67	2.25	3.94
Changes in Operating Assets and Liabilities, net	-1.46	-13	-6.21	-4.48	23	-2.29	-9.91	2.26	-6.10	4.31	-2.37
Net Cash From Investing Activities	33	7.55	17	-0.67	2.80	-89	19	5.05	14	10	-31
Net Cash From Continuing Investing Activities	33	7.55	17	-0.67	2.80	-89	19	5.05	14	10	-31
Purchase of Property, Plant & Equipment	-0.08	-0.44	-0.14	0.01	-	-	-0.04	-0.02	-0.02	-0.02	-0.01
Purchase of Investments	-17	-	0.00	-35	-14	-70	-10.00	-20	-5.20	-4.61	-52
Sale and/or Maturity of Investments	50	7.99	17	35	17	18	30	25	19	15	21
Other Investing Activities, net	-	-	-	-	-	-	-0.83	-	-	-	0.00
Net Cash From Financing Activities	-0.09	0.05	-0.06	-0.01	0.02	75	-0.28	-0.01	-3.04	-2.53	58
Net Cash From Continuing Financing Activities	-0.09	0.05	-0.06	-0.01	0.02	75	-0.28	-0.01	-3.04	-2.53	58
Issuance of Common Equity	-	-	-	-	-	-	0.00	-	-	-	58
Other Financing Activities, net	-0.09	27	-0.06	-0.01	0.02	75	-0.28	-0.01	-3.04	-2.53	-0.10

This table presents Aclaris Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	94	176	244	276	98	71	251	255	197	220	160
Total Current Assets	87	139	200	179	84	57	205	232	129	126	96
Cash & Equivalents	9.85	30	20	57	34	22	27	45	40	25	20
Short-Term Investments	75	107	174	111	39	32	164	172	79	89	71
Other Current Assets	-	-	-	-	-	-	-	-	-	12	5.57
Plant, Property, & Equipment, net	0.36	0.48	2.16	2.29	2.47	1.65	1.34	1.10	1.62	1.01	0.76
Total Noncurrent Assets	7.19	37	41	94	12	12	45	22	67	93	63
Long-Term Investments	7.17	37	15	-	-	0.00	34	12	63	90	61
Other Noncurrent Operating Assets	0.02	0.14	0.28	0.33	4.83	4.51	3.55	2.73	4.16	3.07	2.77
Total Liabilities & Shareholders' Equity	94	176	244	276	98	71	251	255	197	220	160
Total Liabilities	1.56	6.60	18	60	28	33	54	57	40	65	57
Total Current Liabilities	1.56	6.22	13	27	22	15	23	22	31	32	29
Accounts Payable	0.81	2.85	7.82	12	9.92	5.25	9.99	10	8.88	4.69	13
Accrued Expenses	0.75	3.38	4.94	8.09	7.72	5.91	10	8.70	19	20	8.79
Current Deferred Revenue	-	-	-	-	-	-	-	-	0.00	3.89	3.94
Other Current Liabilities	-	-	-	0.14	0.64	0.60	0.69	0.68	2.63	2.68	2.75
Total Noncurrent Liabilities	0.00	0.37	5.49	33	5.95	18	31	35	9.27	33	29
Noncurrent Deferred Revenue	-	-	-	-	-	-	-	-	0.00	20	16
Other Noncurrent Operating Liabilities	0.00	0.37	4.94	1.41	5.40	7.24	31	35	9.27	13	13
Total Equity & Noncontrolling Interests	93	169	225	215	70	38	197	198	157	156	103
Total Preferred & Common Equity	93	169	225	215	70	38	197	198	157	156	103
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	93	169	225	215	70	38	197	198	157	156	103
Common Stock	136	261	385	507	524	542	793	881	928	1,058	1,070
Retained Earnings	-43	-91	-159	-292	-454	-505	-595	-682	-771	-903	-968
Accumulated Other Comprehensive Income / (Loss)	-0.15	-0.27	-0.25	-0.07	-0.07	-0.09	-0.22	-0.90	-0.11	0.10	0.61

This table presents Aclaris Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	236	218	174	161	182	198	189	176	199
Total Current Assets	133	123	135	118	132	109	104	101	110
Cash & Equivalents	31	39	36	23	48	30	25	25	29
Short-Term Investments	89	64	92	88	80	75	74	71	77
Other Current Assets	-	-	-	-	-	-	-	4.68	4.81
Plant, Property, & Equipment, net	1.90	1.76	1.53	1.29	1.13	0.94	0.87	0.81	0.75
Total Noncurrent Assets	101	94	37	42	49	88	84	74	88
Long-Term Investments	91	84	33	39	46	85	81	71	85
Other Noncurrent Operating Assets	2.89	2.66	4.00	3.37	3.22	3.15	2.99	2.83	2.37
Total Liabilities & Shareholders' Equity	236	218	174	161	182	198	189	176	199
Total Liabilities	56	62	32	27	52	54	57	55	55
Total Current Liabilities	23	27	20	16	19	22	27	26	27
Accounts Payable	11	9.65	11	7.27	7.66	6.35	8.80	9.19	15
Accrued Expenses	8.74	15	6.57	5.76	4.72	8.57	11	9.78	5.90
Current Deferred Revenue	-	-	-	-	3.77	3.89	3.91	3.93	3.97
Other Current Liabilities	0.46	0.31	2.71	2.65	2.67	2.70	2.72	2.74	2.77
Total Noncurrent Liabilities	33	35	12	12	33	33	31	30	28
Noncurrent Deferred Revenue	-	-	-	-	21	19	18	17	15
Other Noncurrent Operating Liabilities	33	34	12	12	12	13	12	12	12
Total Equity & Noncontrolling Interests	180	156	142	134	130	144	132	120	144
Total Preferred & Common Equity	180	156	142	134	130	144	132	120	144
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	180	156	142	134	130	144	132	120	144
Common Stock	921	927	930	933	936	1,062	1,065	1,067	1,131
Retained Earnings	-740	-769	-788	-799	-806	-918	-933	-948	-988
Accumulated Other Comprehensive Income / (Loss)	-1.11	-1.13	-0.36	-0.46	0.43	0.43	0.48	0.60	0.02

This table displays calculated financial ratios and metrics derived from Aclaris Therapeutics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	630.96%	-65.64%	53.35%	4.30%	340.05%	5.03%	-40.09%	-58.19%
EBITDA Growth	-140.27%	-134.25%	-12.51%	-42.24%	-39.59%	53.32%	-79.84%	4.26%	-12.06%	-46.25%	46.20%
EBIT Growth	-140.98%	-133.81%	-13.07%	-44.64%	-44.40%	54.79%	-77.00%	4.35%	-12.02%	-45.79%	46.19%
NOPAT Growth	-142.20%	-135.00%	-11.93%	-44.64%	-41.24%	54.16%	-76.23%	-0.15%	-8.35%	-45.79%	46.19%
Net Income Growth	-141.43%	-133.81%	-42.52%	-93.71%	-21.56%	68.38%	-78.11%	4.35%	-1.81%	-49.26%	50.84%
EPS Growth	38.37%	40.63%	-8.44%	-65.16%	3.23%	69.23%	-33.33%	16.88%	4.51%	-34.65%	69.01%
Operating Cash Flow Growth	-166.75%	-69.88%	-57.97%	-84.42%	4.33%	59.94%	-34.95%	-29.60%	-15.92%	74.37%	-134.68%
Free Cash Flow Firm Growth	-198.75%	-84.17%	-104.73%	13.17%	-15.23%	34.34%	-1.49%	-49.76%	-24.43%	-3.09%	29.30%
Invested Capital Growth	166.53%	-1,061.49%	453.32%	-22.67%	-146.59%	54.04%	-861.10%	-14.85%	17.65%	-95.73%	0.13%
Revenue Q/Q Growth	0.00%	0.00%	146.05%	1.50%	-31.62%	17.11%	24.44%	26.60%	45.81%	-30.87%	-50.28%
EBITDA Q/Q Growth	0.00%	-15.21%	7.52%	11.29%	29.20%	-431.89%	-10.33%	-3.92%	20.62%	-210.77%	50.32%
EBIT Q/Q Growth	0.00%	-15.18%	7.25%	10.26%	28.31%	-495.62%	-11.09%	-3.87%	20.45%	-206.53%	50.18%
NOPAT Q/Q Growth	0.00%	-16.35%	7.25%	10.26%	29.87%	-374.65%	-9.69%	-7.39%	20.45%	-206.53%	50.18%
Net Income Q/Q Growth	0.00%	-16.36%	-20.08%	-13.33%	11.01%	9.61%	-11.86%	-5.89%	22.81%	-256.89%	54.18%
EPS Q/Q Growth	0.00%	-183.64%	-13.49%	-5.50%	12.16%	10.45%	-2.56%	-5.56%	23.49%	-228.85%	66.46%
Operating Cash Flow Q/Q Growth	-7.24%	-12.83%	-22.77%	-9.85%	6.64%	22.99%	-18.71%	-3.11%	13.62%	-12.16%	-9.77%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	2.07%	9.93%	31.30%	-4,818.52%	-19.50%	-2.85%	11.76%	-330.45%	48.29%
Invested Capital Q/Q Growth	0.00%	-59.04%	-0.02%	5.24%	53.50%	-385.18%	-5.13%	-15.25%	13.22%	-11.68%	-2.49%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	28.28%	64.81%	4.07%	20.81%	30.29%	86.48%	89.05%	85.09%	73.28%
EBITDA Margin	0.00%	0.00%	-3,206.12%	-623.88%	-2,534.49%	-771.55%	-1,330.31%	-289.43%	-308.79%	-753.87%	-970.11%
Operating Margin	0.00%	0.00%	-3,230.01%	-639.16%	-2,627.35%	-785.44%	-1,327.07%	-302.01%	-311.55%	-758.18%	-975.91%
EBIT Margin	0.00%	0.00%	-3,230.01%	-639.16%	-2,686.11%	-791.98%	-1,343.96%	-292.11%	-311.55%	-758.18%	-975.91%
Profit (Net Income) Margin	0.00%	0.00%	-4,071.48%	-1,079.00%	-3,817.22%	-787.03%	-1,343.96%	-292.11%	-283.15%	-705.48%	-829.58%
Tax Burden Percent	100.00%	100.00%	97.40%	161.67%	142.11%	99.37%	100.00%	100.00%	99.59%	100.00%	85.01%
Interest Burden Percent	100.00%	100.00%	129.42%	104.42%	100.00%	100.00%	100.00%	100.00%	91.26%	93.05%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-646.93%	-378.32%	-2,294.25%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-631.02%	-340.54%	-2,234.15%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	612.22%	318.04%	2,181.03%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-37.92%	-36.70%	-34.72%	-60.28%	-113.22%	-94.86%	-77.33%	-44.01%	-49.88%	-84.46%	-50.20%
Cash Return on Invested Capital (CROIC)	-3,245.53%	0.00%	-360.22%	-352.76%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	-25.91%	-30.30%	-60.74%	-60.72%	-56.44%	-34.36%	-43.08%	-67.95%	-40.11%
Return on Assets (ROA)	0.00%	0.00%	-32.66%	-51.14%	-86.32%	-60.34%	-56.44%	-34.36%	-39.15%	-63.23%	-34.10%
Return on Common Equity (ROCE)	-25.10%	-36.70%	-34.72%	-60.28%	-113.22%	-94.86%	-77.33%	-44.01%	-49.88%	-84.46%	-50.20%
Return on Equity Simple (ROE_SIMPLE)	-22.23%	-28.37%	-30.42%	-61.70%	-230.80%	-135.50%	-46.04%	-43.98%	-56.29%	-84.90%	0.00%
Net Operating Profit after Tax (NOPAT)	-14	-34	-38	-55	-78	-36	-63	-63	-68	-99	-53
NOPAT Margin	0.00%	0.00%	-2,261.00%	-447.41%	-1,839.14%	-549.81%	-928.95%	-211.41%	-218.09%	-530.73%	-683.14%
Net Nonoperating Expense Percent (NNEP)	-11.22%	-10.58%	-15.91%	-37.78%	-60.10%	-26.47%	-21.27%	-10.65%	-9.93%	-16.96%	-6.45%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-43.36%	-63.87%	-51.86%
Cost of Revenue to Revenue	0.00%	0.00%	71.72%	35.19%	95.93%	79.19%	69.71%	13.52%	10.95%	14.91%	26.72%
SG&A Expenses to Revenue	0.00%	0.00%	1,125.85%	209.41%	658.32%	316.72%	349.34%	84.48%	103.72%	118.61%	280.76%
R&D to Revenue	0.00%	0.00%	2,127.39%	494.56%	1,517.98%	452.61%	648.03%	261.54%	336.05%	643.65%	672.69%
Operating Expenses to Revenue	0.00%	0.00%	3,258.29%	703.97%	2,631.42%	806.25%	1,357.36%	388.49%	400.60%	843.27%	1,049.20%
Earnings before Interest and Taxes (EBIT)	-21	-48	-54	-79	-114	-51	-91	-87	-97	-142	-76
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-20	-48	-54	-77	-107	-50	-90	-86	-96	-141	-76
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.87	3.43	3.38	1.41	1.12	7.38	4.51	5.31	0.47	1.14	3.16
Price to Tangible Book Value (P/TBV)	5.87	3.43	3.81	1.60	1.25	9.10	4.68	5.51	0.47	1.14	3.16
Price to Revenue (P/Rev)	0.00	0.00	451.80	24.59	18.51	42.84	131.67	35.30	2.38	9.46	41.67
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	933.76	0.00	33.61	12.96	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	327.71	13.37	0.76	36.13	98.30	27.58	0.00	0.00	22.33
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.14	0.00	0.28	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.14	0.00	0.28	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.00	-1.02	-0.97	-0.93	-0.98	-1.08	-1.12	-1.14	-1.15	-1.23	-1.37
Leverage Ratio	1.03	1.03	1.06	1.18	1.31	1.57	1.37	1.28	1.27	1.34	1.47
Compound Leverage Factor	1.03	1.03	1.38	1.23	1.31	1.57	1.37	1.28	1.16	1.24	1.47
Debt to Total Capital	0.00%	0.00%	0.00%	12.21%	0.00%	22.05%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	12.21%	0.00%	22.05%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	87.79%	100.00%	77.95%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	-0.39	0.00	-0.21	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	1.80	0.00	0.87	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	-0.39	0.00	-0.21	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	-0.54	0.00	-0.30	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	2.51	0.00	1.22	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	-0.54	0.00	-0.30	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	209.26	52.20	24.28	1.28	-7.83	-6.53	6.30	7.29	-5.23	-5.62	-6.05
Noncontrolling Interest Sharing Ratio	33.82%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	55.64	22.27	15.69	6.57	3.74	3.87	8.94	10.55	4.16	3.99	3.36
Quick Ratio	54.58	22.05	15.23	6.16	3.30	3.69	8.37	9.94	3.86	3.61	3.17
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-16	-29	-59	-51	-59	-39	-39	-59	-73	-76	-54
Operating Cash Flow to CapEx	-4,017.55%	-14,915.09%	-4,426.15%	-7,434.44%	-5,979.23%	-8,528.26%	-16,926.62%	-11,168.10%	-5,983.58%	-16,590.91%	-42,444.14%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.01	0.05	0.02	0.08	0.04	0.12	0.14	0.09	0.04
Accounts Receivable Turnover	0.00	0.00	0.00	23.57	6.67	8.78	9.69	53.75	79.92	60.78	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	1.28	5.53	1.78	3.14	4.52	24.45	22.99	14.25	8.85
Accounts Payable Turnover	0.00	0.00	0.23	0.44	0.38	0.68	0.62	0.40	0.36	0.41	0.23
Days Sales Outstanding (DSO)	0.00	0.00	0.00	15.49	54.70	41.56	37.66	6.79	4.57	6.01	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	1,612.86	821.95	971.77	539.39	590.10	922.53	1,025.21	886.88	1,557.75
Cash Conversion Cycle (CCC)	0.00	0.00	-1,612.86	-806.46	-917.07	-497.84	-552.44	-915.74	-1,020.64	-880.87	-1,557.75
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.48	-4.64	16	13	-5.91	-2.72	-26	-30	-25	-48	-48
Invested Capital Turnover	0.00	0.00	0.29	0.85	1.25	-1.50	-0.47	-1.06	-1.14	-0.51	-0.16
Increase / (Decrease) in Invested Capital	1.21	-5.13	21	-3.72	-19	3.20	-23	-3.88	5.29	-24	0.06
Enterprise Value (EV)	451	408	552	164	3.21	234	665	820	-107	-27	175
Market Capitalization	543	582	760	303	78	278	890	1,050	74	177	326
Book Value per Share	$4.59	$7.91	$7.31	$5.26	$1.69	$0.88	$3.22	$2.96	$2.22	$2.18	$0.95
Tangible Book Value per Share	$4.59	$7.91	$6.47	$4.63	$1.52	$0.71	$3.11	$2.86	$2.22	$2.18	$0.95
Total Capital	93	169	225	245	70	48	197	198	157	156	103
Total Debt	0.00	0.00	0.00	30	0.00	11	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	30	0.00	11	0.00	0.00	0.00	0.00	0.00
Net Debt	-92	-174	-209	-138	-75	-43	-226	-230	-182	-204	-151
Capital Expenditures (CapEx)	0.51	0.23	1.24	1.36	1.61	0.45	0.31	0.61	1.31	0.12	0.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.10	-4.89	-6.40	-16	-14	-12	-9.31	-7.96	-21	-19	-23
Debt-free Net Working Capital (DFNWC)	85	132	187	152	61	43	182	210	98	94	68
Net Working Capital (NWC)	85	132	187	152	61	43	182	210	98	94	68
Net Nonoperating Expense (NNE)	6.10	14	30	78	84	15	28	24	20	33	11
Net Nonoperating Obligations (NNO)	-92	-174	-209	-202	-76	-40	-223	-228	-182	-204	-151
Total Depreciation and Amortization (D&A)	0.09	0.12	0.40	1.88	6.41	1.32	0.92	0.80	0.86	0.81	0.45
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	-380.15%	-128.56%	-322.78%	-177.60%	-137.75%	-26.75%	-67.85%	-102.77%	-294.91%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	11,138.38%	1,236.85%	1,451.88%	657.50%	2,693.40%	704.53%	313.30%	504.03%	864.69%
Net Working Capital to Revenue	0.00%	0.00%	11,138.38%	1,236.85%	1,451.88%	657.50%	2,693.40%	704.53%	313.30%	504.03%	864.69%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($3.79)	($2.25)	($2.44)	($4.03)	($3.90)	($1.20)	($1.60)	($1.33)	($1.27)	($1.71)	($0.53)
Adjusted Weighted Average Basic Shares Outstanding	20.16M	26.09M	30.90M	41.27M	41.53M	51.80M	56.73M	65.21M	69.81M	77.30M	122.56M
Adjusted Diluted Earnings per Share	($3.79)	($2.25)	($2.44)	($4.03)	($3.90)	($1.20)	($1.60)	($1.33)	($1.27)	($1.71)	($0.53)
Adjusted Weighted Average Diluted Shares Outstanding	20.16M	26.09M	30.90M	41.27M	41.53M	51.80M	56.73M	65.21M	69.81M	77.30M	122.56M
Adjusted Basic & Diluted Earnings per Share	($3.79)	($2.25)	($2.44)	($4.03)	($3.90)	($1.20)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	6.11M	21.42M	28.10M	32.91M	41.32M	42.54M	61.28M	66.69M	70.93M	107.92M	120.60M
Normalized Net Operating Profit after Tax (NOPAT)	-14	-34	-38	-55	-64	-34	-46	-60	-87	-98	-52
Normalized NOPAT Margin	0.00%	0.00%	-2,261.00%	-447.41%	-1,520.56%	-523.96%	-676.95%	-200.35%	-278.34%	-521.38%	-662.57%
Pre Tax Income Margin	0.00%	0.00%	-4,180.21%	-667.40%	-2,686.11%	-791.98%	-1,343.96%	-292.11%	-284.32%	-705.48%	-975.91%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-0.41%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Aclaris Therapeutics' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	70,794,642.00	70,836,194.00	70,836,194.00	71,264,786.00	71,344,557.00	-	107,918,821.00	108,281,239.00	108,332,218.00	-	120,595,189.00
DEI Adjusted Shares Outstanding	70,794,642.00	70,836,194.00	70,836,194.00	71,264,786.00	71,344,557.00	-	107,918,821.00	108,281,239.00	108,332,218.00	-	120,595,189.00
DEI Earnings Per Adjusted Shares Outstanding	-0.41	-0.02	-0.24	-0.15	-0.11	-	-0.14	-0.14	-0.13	-	-0.16
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-51.19%	126.62%	-5.14%	47.99%	-53.18%	-47.58%	-39.32%	-35.76%	-24.09%	-85.94%	37.18%
EBITDA Growth	-51.63%	86.78%	33.17%	60.08%	67.18%	-2,506.26%	3.92%	-45.05%	-65.56%	77.26%	-23.02%
EBIT Growth	-51.27%	86.08%	32.77%	59.60%	66.84%	-2,362.96%	4.47%	-43.21%	-63.78%	77.19%	-22.72%
NOPAT Growth	-51.27%	80.12%	36.72%	59.60%	66.84%	-1,624.07%	4.47%	-43.21%	-63.78%	77.19%	-22.72%
Net Income Growth	-46.66%	94.60%	39.84%	62.85%	74.07%	-6,375.65%	10.96%	-40.44%	-92.64%	79.50%	-31.42%
EPS Growth	-36.67%	95.12%	42.86%	64.29%	73.17%	-5,950.00%	50.00%	13.33%	-9.09%	86.78%	-25.00%
Operating Cash Flow Growth	-214.15%	64.63%	21.01%	40.34%	189.59%	-32.20%	37.27%	18.90%	-149.69%	-46.91%	-39.00%
Free Cash Flow Firm Growth	-46.45%	43.33%	-15.35%	-92.17%	138.11%	-393.94%	174.89%	192.89%	-209.15%	65.37%	-202.80%
Invested Capital Growth	-9.37%	17.65%	23.79%	44.30%	-52.09%	-95.73%	-140.09%	-206.26%	-8.83%	0.13%	-1.46%
Revenue Q/Q Growth	396.63%	89.29%	-86.35%	15.35%	57.12%	111.92%	-84.20%	22.13%	85.65%	-60.75%	54.13%
EBITDA Q/Q Growth	0.76%	87.82%	-389.34%	32.51%	18.40%	-867.09%	81.96%	-1.88%	6.86%	-32.82%	2.39%
EBIT Q/Q Growth	0.75%	87.18%	-367.78%	32.10%	18.54%	-851.92%	81.86%	-1.79%	6.84%	-32.57%	2.38%
NOPAT Q/Q Growth	0.75%	81.69%	-227.45%	32.10%	18.54%	-851.92%	81.86%	-1.79%	6.84%	-32.57%	2.38%
Net Income Q/Q Growth	1.04%	94.90%	-1,036.22%	35.15%	30.95%	-1,172.77%	84.38%	-2.28%	5.28%	-35.45%	-0.15%
EPS Q/Q Growth	2.38%	95.12%	-1,100.00%	37.50%	26.67%	-1,000.00%	90.08%	-8.33%	7.69%	-33.33%	6.25%
Operating Cash Flow Q/Q Growth	-18.90%	72.47%	-207.87%	40.80%	278.54%	-140.63%	-46.08%	23.47%	-9.40%	-20.12%	-38.21%
Free Cash Flow Firm Q/Q Growth	-73.63%	52.51%	-106.59%	-12.80%	134.43%	-715.52%	131.32%	39.91%	-140.46%	-95.28%	7.01%
Invested Capital Q/Q Growth	1.23%	13.22%	21.65%	17.06%	-169.71%	-11.68%	3.90%	-5.79%	4.15%	-2.49%	2.37%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	90.86%	95.87%	66.26%	77.44%	84.95%	92.35%	65.22%	71.02%	83.69%	58.92%	80.21%
EBITDA Margin	-337.84%	-21.74%	-779.32%	-455.97%	-236.82%	-1,080.71%	-1,234.09%	-1,029.49%	-516.49%	-1,747.64%	-1,106.71%
Operating Margin	-340.20%	-23.03%	-789.45%	-464.71%	-240.93%	-1,082.26%	-1,242.89%	-1,035.90%	-519.82%	-1,755.52%	-1,111.82%
EBIT Margin	-340.20%	-23.03%	-789.45%	-464.71%	-240.93%	-1,082.26%	-1,242.89%	-1,035.90%	-519.82%	-1,755.52%	-1,111.82%
Profit (Net Income) Margin	-315.24%	-8.49%	-706.46%	-397.18%	-174.55%	-1,048.34%	-1,036.77%	-868.26%	-442.98%	-1,528.57%	-993.19%
Tax Burden Percent	92.67%	-55.14%	89.49%	85.47%	72.45%	105.32%	83.42%	83.82%	85.22%	87.07%	89.33%
Interest Burden Percent	100.00%	-66.81%	100.00%	100.00%	100.00%	91.98%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-60.94%	-49.88%	-48.47%	-37.43%	-25.83%	-84.46%	-91.03%	-101.41%	-113.23%	-50.20%	-48.42%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-30.01%	-3.18%	-121.69%	-75.01%	-32.56%	-97.00%	-118.74%	-99.31%	-45.72%	-72.16%	-46.89%
Return on Assets (ROA)	-27.80%	-1.17%	-108.90%	-64.11%	-23.59%	-93.96%	-99.05%	-83.24%	-38.96%	-62.83%	-41.88%
Return on Common Equity (ROCE)	-60.94%	-49.88%	-48.47%	-37.43%	-25.83%	-84.46%	-91.03%	-101.41%	-113.23%	-50.20%	-48.42%
Return on Equity Simple (ROE_SIMPLE)	-73.32%	0.00%	-54.40%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-22	-4.05	-13	-9.00	-7.33	-70	-13	-13	-12	-16	-16
NOPAT Margin	-238.14%	-23.03%	-552.61%	-325.30%	-168.65%	-757.58%	-870.02%	-725.13%	-363.88%	-1,228.86%	-778.28%
Net Nonoperating Expense Percent (NNEP)	-3.32%	1.25%	-2.03%	-1.11%	-0.14%	-13.88%	-1.38%	-1.54%	-1.53%	-2.19%	-2.25%
Return On Investment Capital (ROIC_SIMPLE)	-	-2.57%	-9.33%	-6.72%	-5.63%	-44.85%	-8.79%	-9.78%	-10.00%	-15.44%	-10.81%
Cost of Revenue to Revenue	9.14%	4.13%	33.74%	22.56%	15.05%	7.65%	34.78%	28.98%	16.31%	41.08%	19.79%
SG&A Expenses to Revenue	76.40%	46.75%	285.40%	171.80%	130.07%	53.79%	421.92%	303.10%	147.65%	430.58%	337.83%
R&D to Revenue	257.23%	189.39%	410.55%	316.67%	137.05%	1,041.60%	796.15%	644.29%	394.91%	1,280.62%	784.42%
Operating Expenses to Revenue	431.06%	118.91%	855.71%	542.15%	325.89%	1,174.60%	1,308.11%	1,106.92%	603.52%	1,814.44%	1,192.03%
Earnings before Interest and Taxes (EBIT)	-32	-4.05	-19	-13	-10	-100	-18	-18	-17	-23	-22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-31	-3.82	-19	-13	-10	-100	-18	-18	-17	-23	-22
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.10	0.47	0.62	0.59	0.63	1.14	1.15	1.17	1.71	3.16	3.15
Price to Tangible Book Value (P/TBV)	3.25	0.47	0.62	0.59	0.63	1.14	1.15	1.17	1.71	3.16	3.15
Price to Revenue (P/Rev)	22.63	2.38	2.82	2.45	3.03	9.46	9.29	9.16	13.08	41.67	54.05
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	13.90	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.45	22.33	31.25
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.14	-1.15	-1.14	-1.14	-1.25	-1.23	-1.23	-1.25	-1.36	-1.37	-1.33
Leverage Ratio	1.29	1.27	1.27	1.27	1.40	1.34	1.30	1.32	1.43	1.47	1.38
Compound Leverage Factor	1.29	-0.85	1.27	1.27	1.40	1.23	1.30	1.32	1.43	1.47	1.38
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-0.09	-3.67	-4.08	-4.52	-4.54	-4.99	-4.34	-5.04	-5.05	-4.95	-1.86
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.50	4.16	6.74	7.50	7.03	3.99	5.06	3.88	3.92	3.36	4.03
Quick Ratio	3.78	3.86	6.40	7.10	6.81	3.61	4.91	3.73	3.74	3.17	3.85
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-20	-9.34	-19	-22	7.49	-46	14	20	-8.18	-16	-15
Operating Cash Flow to CapEx	-29,234.52%	-1,533.11%	-15,418.52%	0.00%	0.00%	0.00%	-30,365.12%	-47,585.71%	-47,530.43%	-54,712.50%	-139,607.69%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.09	0.14	0.15	0.16	0.14	0.09	0.10	0.10	0.09	0.04	0.04
Accounts Receivable Turnover	45.45	79.92	58.77	84.70	78.61	60.78	57.07	64.69	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	14.74	22.99	20.45	20.06	18.70	14.25	14.38	15.54	16.19	8.85	9.89
Accounts Payable Turnover	0.41	0.36	0.36	0.32	0.32	0.41	0.29	0.30	0.27	0.23	0.19
Days Sales Outstanding (DSO)	8.03	4.57	6.21	4.31	4.64	6.01	6.40	5.64	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	883.91	1,025.21	1,012.70	1,134.95	1,123.43	886.88	1,258.51	1,231.95	1,358.19	1,557.75	1,943.44
Cash Conversion Cycle (CCC)	-875.88	-1,020.64	-1,006.49	-1,130.64	-1,118.78	-880.87	-1,252.11	-1,226.31	-1,358.19	-1,557.75	-1,943.44
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-28	-25	-19	-16	-43	-48	-46	-49	-47	-48	-47
Invested Capital Turnover	-0.79	-1.14	-1.39	-1.43	-0.75	-0.51	-0.54	-0.52	-0.35	-0.16	-0.18
Increase / (Decrease) in Invested Capital	-2.44	5.29	6.04	13	-15	-24	-27	-33	-3.82	0.06	-0.68
Enterprise Value (EV)	298	-107	-74	-71	-91	-27	-25	-27	39	175	261
Market Capitalization	485	74	88	78	82	177	165	154	206	326	452
Book Value per Share	$2.21	$2.22	$2.00	$1.88	$1.82	$2.18	$1.33	$1.22	$1.11	$0.95	$1.19
Tangible Book Value per Share	$2.11	$2.22	$2.00	$1.88	$1.82	$2.18	$1.33	$1.22	$1.11	$0.95	$1.19
Total Capital	156	157	142	134	130	156	144	132	120	103	144
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-187	-182	-161	-150	-173	-204	-191	-181	-167	-151	-191
Capital Expenditures (CapEx)	0.08	0.44	0.14	-0.01	0.00	0.00	0.04	0.02	0.02	0.02	0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-7.30	-21	-13	-9.14	-14	-19	-18	-22	-21	-23	-23
Debt-free Net Working Capital (DFNWC)	96	98	115	102	114	94	87	77	75	68	83
Net Working Capital (NWC)	96	98	115	102	114	94	87	77	75	68	83
Net Nonoperating Expense (NNE)	7.16	-2.56	3.69	1.99	0.26	27	2.43	2.54	2.61	3.88	4.29
Net Nonoperating Obligations (NNO)	-185	-182	-161	-150	-173	-204	-191	-181	-167	-151	-191
Total Depreciation and Amortization (D&A)	0.22	0.23	0.24	0.24	0.18	0.14	0.13	0.11	0.11	0.10	0.10
Debt-free, Cash-free Net Working Capital to Revenue	-34.08%	-67.85%	-41.48%	-28.55%	-52.47%	-102.77%	-101.47%	-133.68%	-133.10%	-294.91%	-269.58%
Debt-free Net Working Capital to Revenue	446.75%	313.30%	370.38%	318.44%	419.18%	504.03%	490.95%	460.82%	476.22%	864.69%	990.32%
Net Working Capital to Revenue	446.75%	313.30%	370.38%	318.44%	419.18%	504.03%	490.95%	460.82%	476.22%	864.69%	990.32%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.41)	($0.02)	($0.24)	($0.15)	($0.11)	($1.21)	($0.12)	($0.13)	($0.12)	($0.16)	($0.15)
Adjusted Weighted Average Basic Shares Outstanding	70.81M	69.81M	71.07M	71.29M	71.38M	77.30M	122.39M	122.58M	122.62M	122.56M	128.81M
Adjusted Diluted Earnings per Share	($0.41)	($0.02)	($0.24)	($0.15)	($0.11)	($1.21)	($0.12)	($0.13)	($0.12)	($0.16)	($0.15)
Adjusted Weighted Average Diluted Shares Outstanding	70.81M	69.81M	71.07M	71.29M	71.38M	77.30M	122.39M	122.58M	122.62M	122.56M	128.81M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	70.84M	70.93M	71.26M	71.34M	71.43M	107.92M	108.28M	108.33M	108.35M	120.60M	139.66M
Normalized Net Operating Profit after Tax (NOPAT)	-21	-21	-11	-8.86	-6.77	-71	-12	-12	-12	-16	-16
Normalized NOPAT Margin	-225.32%	-120.90%	-470.88%	-320.24%	-155.77%	-767.46%	-855.59%	-666.04%	-361.76%	-1,207.24%	-778.28%
Pre Tax Income Margin	-340.20%	15.39%	-789.45%	-464.71%	-240.93%	-995.41%	-1,242.89%	-1,035.90%	-519.82%	-1,755.52%	-1,111.82%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Aclaris Therapeutics (NASDAQ: ACRS) continues to operate like a development-stage biotech with meaningful cash reserves, modest revenue, and persistent operating losses. The latest Q1 2026 results show some improvement in cash generation compared with prior quarters, but the company is still burning cash overall and remains dependent on its balance sheet and financing flexibility.

Q1 2026 ended with $110.2 million in current assets, including $28.7 million in cash and $76.8 million in short-term investments, giving Aclaris a solid near-term liquidity cushion.
The company also holds $85.4 million in long-term investments, lifting total assets to $198.7 million.
Despite the loss, Aclaris generated a $8.7 million increase in cash and equivalents in Q1 2026, helped by $57.9 million of common equity issuance.
Revenue rose to $2.0 million in Q1 2026 from $1.3 million in Q4 2025 and $1.5 million in Q1 2025, showing some top-line growth.
Gross profit improved to $1.6 million in Q1 2026, with gross margin remaining strong for a small biotech at roughly 80%.
Operating expenses remain heavy, with R&D at $15.7 million and SG&A at $6.7 million in Q1 2026.
The quarterly net loss was $19.8 million, roughly in line with recent quarters, indicating losses are still substantial but not accelerating dramatically.
Basic and diluted EPS were both $(0.15) in Q1 2026, compared with $(0.16) in Q4 2025 and $(0.12) in Q3 2025.
Aclaris has continued to manage its asset base conservatively, with only minimal capital spending in Q1 2026 of $13,000 on property and equipment.
The company still posted negative operating cash flow of $18.1 million in Q1 2026, so the business is not yet self-funding.
From a longer-term view, revenue remains volatile and small relative to expenses, while annual operating losses have been very large over the past four years.
Share dilution is a real concern: weighted average basic shares rose to 128.8 million in Q1 2026 from 122.6 million in Q4 2025 and 71.0 million in Q1 2024.
Book equity has weakened over time, with retained earnings still deeply negative at $(987.6) million, reflecting years of accumulated losses.

Bottom line: Aclaris has enough liquidity to keep working on its pipeline for now, and Q1 2026 showed a better cash position than the company had a year ago. Still, the core financial picture hasn’t changed much: revenue is small, losses are recurring, and cash needs are being supported by investment balances and equity raises rather than operating performance.

05/21/26 07:34 AM ETAI Generated. May Contain Errors.

Aclaris Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Aclaris Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Aclaris Therapeutics' net income appears to be on an upward trend, with a most recent value of -$64.92 million in 2025, rising from -$20.56 million in 2015. The previous period was -$132.07 million in 2024. Check out Aclaris Therapeutics' forecast to explore projected trends and price targets.

Aclaris Therapeutics' total operating income in 2025 was -$76.38 million, based on the following breakdown:

Total Gross Profit: $5.74 million
Total Operating Expenses: $82.11 million

Over the last 10 years, Aclaris Therapeutics' total revenue changed from $0.00 in 2015 to $7.83 million in 2025, a change of 782,600,000.0%.

Aclaris Therapeutics' total liabilities were at $57.38 million at the end of 2025, a 11.4% decrease from 2024, and a 3,589.9% increase since 2015.

In the past 10 years, Aclaris Therapeutics' cash and equivalents has ranged from $9.85 million in 2015 to $57.02 million in 2018, and is currently $19.96 million as of their latest financial filing in 2025.

Over the last 10 years, Aclaris Therapeutics' book value per share changed from 4.59 in 2015 to 0.95 in 2025, a change of -79.3%.

Related Companies

Financial statements for NASDAQ:ACRS last updated on 5/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aclaris Therapeutics (ACRS) Financials

Financials Breakdown Chart

Key Financial Trends

Aclaris Therapeutics Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aclaris Therapeutics (ACRS) Financials

Annual Income Statements for Aclaris Therapeutics

Quarterly Income Statements for Aclaris Therapeutics

Annual Cash Flow Statements for Aclaris Therapeutics

Quarterly Cash Flow Statements for Aclaris Therapeutics

Annual Balance Sheets for Aclaris Therapeutics

Quarterly Balance Sheets for Aclaris Therapeutics

Annual Metrics And Ratios for Aclaris Therapeutics

Quarterly Metrics And Ratios for Aclaris Therapeutics

Financials Breakdown Chart

Key Financial Trends

Aclaris Therapeutics Financials - Frequently Asked Questions

When does Aclaris Therapeutics' fiscal year end?

How has Aclaris Therapeutics' net income changed over the last 10 years?

What is Aclaris Therapeutics' operating income?

How has Aclaris Therapeutics' revenue changed over the last 10 years?

How much debt does Aclaris Therapeutics have?

How much cash does Aclaris Therapeutics have?

How has Aclaris Therapeutics' book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools